Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
FDA Grants Breakthrough and RMAT Status to Aurion’s AURN001
Aurion Biotech has been granted Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) Designation by the FDA for AURN001, Aurion’s innovative allogeneic cell therapy candidate designed to treat corneal edema secondary to corneal endothelial disease. Expediting Development and…
RevOpsis and Kemwell Form Manufacturing Partnership for nAMD
RevOpsis Therapeutics and Kemwell Biopharma have forged a strategic manufacturing partnership aimed at accelerating the development of RO-104, a pioneering tri-specific biologic designed by RevOpsis for treating neovascular age-related macular degeneration (nAMD). Neovascular age-related macular degeneration (nAMD) is a progressive…
Study Identifies Risk Factors for Hydroxychloroquine Retinopathy
A recent study published online in JAMA Network Open sheds light on factors associated with an increased risk for hydroxychloroquine retinopathy. The research, led by April M. Jorge, M.D., from Massachusetts General Hospital in Boston, identifies crucial risk factors beyond…
What is X-Linked Retinitis Pigmentosa
Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother…
Metformin Found Ineffective Against Geographic Atrophy
In the quest to find effective treatments for eye diseases, the METformin for the MINimization of Geographic Atrophy Progression (METforMIN) trial sought to evaluate the efficacy of oral metformin in slowing the progression of geographic atrophy (GA) and its effects…
Nordic Pharma Introduces Lacrifill Canalicular Gel for Dry Eye
Nordic Pharma announced the commercial launch of Lacrifill Canalicular Gel, aimed at addressing dry eye disease in the United States. This novel therapy, Lacrifill, is a cross-linked hyaluronic acid derivative that has received clearance from the FDA. Its primary function…
New Device Targets Dry Eye and Beyond with Thermal Imaging
A groundbreaking innovation in ocular health assessment is on the horizon, as a new University of Waterloo spinoff company, ThermOcular AI, unveils its pioneering approach to eye temperature monitoring. Transforming Ocular Diagnostics Founded by vision science and engineering researchers from…
Teprotumumab Shows Long-Lasting Benefits for TED Patients
Research presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Massachusetts, and published in the journal Thyroid, indicates that most patients with thyroid eye disease (TED) treated with teprotumumab did not require additional treatments nearly two years later.…
Beacon Therapeutics Initiates VISTA Trial for X-Linked RP
Beacon Therapeutics announced the treatment of the inaugural patient in its pivotal VISTA clinical trial with its lead asset, AGTC-501 (laruparetigene zovaparvovec), marking a significant advancement in the pursuit of combating X-Linked Retinitis Pigmentosa (XLRP). Objective of the VISTA Trial…
Robot Radiotherapy Could Improve Treatment for AMD
Researchers from King’s College London, in collaboration with doctors at King’s College Hospital NHS Foundation Trust, have achieved a breakthrough in treating a debilitating eye disease using a new robot system. This system targets wet neovascular age-related macular degeneration (AMD)…